Extended Data Table 1 Baseline Demographics and Disease Characteristics According to Treatment Assignment and Underlying Tafamidis Treatment

From: Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial

  1. Values are n (%), mean ± SD, or median (IQR). Race was self-reported. *NAC stage classifies patients according to NT-proBNP and eGFR levels: Stage 1 (lower risk) is defined as NT-proBNP ≤3000 pg/mL and eGFR ≥45 mL/min/1.73 m2; stage 2 (intermediate risk) includes patients not meeting stage 1 or 3 criteria; stage 3 (higher risk) is defined as NT-proBNP 3000 pg/mL and eGFR 45 mL/min/1.73 m2. 6-MWT – 6-minute walk test, ATTR – transthyretin amyloidosis, eGFR – estimated glomerular filtration rate, IQR – interquartile range, KCCQ-OS – Kansas City Cardiomyopathy Questionnaire-Overall Summary; NAC – National Amyloidosis Centre; NT-proBNP – N-terminal pro-B-type natriuretic peptide, NYHA – New York Heart Association, SD – standard deviation.
Back to article page